GAZYVA: payments to doctors
Payments that named GAZYVA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $4.4M
- Providers
- 4,571
- Transactions
- 10,994
- Average per transaction
- $400
The per-transaction average — $400 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,571 providers the average total is $963, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $3,064,915 | 69.6% |
| Genentech USA, Inc. | $1,205,231 | 27.4% |
| F. Hoffmann-la Roche AG | $74,122 | 1.7% |
| Roche Products Limited | $56,750 | 1.3% |
| Chugai Pharmaceutical Co., Ltd. | $1,980 | 0.0% |